In a nutshell This study looked at the safety and effectiveness of lenalidomide (Revlimid) to treat patients with relapsed diffuse large B-cell lymphoma. The authors concluded that lenalidomide is safe and effective for treating patients with relapsed diffuse large B-cell lymphoma, especially in patients with non-germinal center B-cell (GCB) like...
Read MoreCurrent treatment status-Undergoing active treatment-No response Posts on Medivizor
Long-term outcomes of allogeneic stem cell transplantations in young high-risk CLL patients
In a nutshell This study examined predictors of outcomes with stem cell transplantation from a donor (allo-SCT) for chronic lymphocytic leukemia (CLL). Researchers reported good long-term outcomes for young high-risk CLL patients treated with allo-SCT. Patients with matched sibling donors showed better outcomes compared to those with matched unrelated...
Read MoreReview of obinutuzumab for follicular lymphoma patients who failed rituximab treatments
In a nutshell This article reviewed the use of obinutuzumab for patients with follicular lymphoma who have failed rituximab treatment. The article concluded that obinutuzumab treatment is useful for follicular lymphoma patients who have not responded well to rituximab regimens. Some background Follicular lymphoma (FL) is a common type...
Read MoreCAR-T cells to treat chronic lymphocytic leukemia after failure of ibrutinib
In a nutshell This paper studied the effect of lymphodepletion chemotherapy and CAR-T cell infusion in patients with chronic lymphocytic leukemia who did not respond to ibrutinib (Imbruvica) therapy. This was found to be a highly effective treatment. Some background Chronic lymphocytic leukemia (CLL) is a cancer of the blood forming cells....
Read MoreLooking for patients with relapsed follicular, marginal zone, or mantle cell lymphoma to test the effectiveness of a rituximab and lenalidomide maintenance therapy
In a nutshell This phase 3 clinical trial will test the effectiveness of a lenalidomide (Revlimid) and rituximab (Rituxan) maintenance therapy followed by rituximab and lenalidomide or rituximab only in treating relapsed follicular, marginal zone, or mantle cell lymphoma. The primary outcome will be measured by the time to disease progression....
Read MoreSearching for patients with relapsed/refractory mantle cell lymphoma or newly diagnosed elderly patients to test the effectiveness of ibrutinib with rituximab
In a nutshell This phase 2 clinical trial will test the effectiveness of an ibrutinib (Imbruvica) and rituximab (Rituxan) combination in treating patients with relapsed or refractory mantle cell lymphoma (MCL) or newly diagnosed elderly patients. The primary objective will be measured by the response rate. This trial is being conducted...
Read MoreLooking for patients with relapsed or refractory cutaneous lymphoma to test a novel immunotherapy
In a nutshell This phase 1/2 clinical trial will test the response to AFM13 in patients with relapsed or refractory cutaneous (on the skin) CD30 positive lymphomas. The primary outcome will be measured by immune system activity. This study will be conducted at the Center for Lymphoid Malignancies in New York, New York. The details AFM13 is an...
Read MoreSearching for patients with relapsed or refractory follicular lymphoma to test the effectiveness of TGR-1202
In a nutshell This phase 2 clinical trial will test the effectiveness of TGR-1202 in patients with relapsed or refractory follicular lymphoma. The primary outcome will be measured by the overall response rate. This trial is being conducted at the Columbia University Medical Center in New York, New York. The details TGR-1202 (umbralisib)...
Read MoreSearching for patients with relapsed or refractory non-Hodgkin’s lymphoma to test the effectiveness of a PI3K inhibitor alone or with other drugs
In a nutshell This phase 2 clinical trial will test the effectiveness and safety of ublituximab (TG-1101) and TGR-1202 with or without bendamustine (Treanda), as well as TGR-1202 alone in treating patients with relapsed or refractory non-Hodgkin’s lymphoma. The primary outcome will be measured by the overall response. The details...
Read MoreLooking for patients with chronic myelogenous leukemia or Philadelphia chromosome positive acute lympholastic leukemia to test a BCR-ABL1 inhibitor
In a nutshell This phase 1 clinical trial will test the safety of ABL001 alone and with either nilotinib (Tasigna), imatinib (Gleevec), or dasatinib (Sprycel) in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic Leukemia (Ph+ALL). The primary outcome will be measured by side effects. The details...
Read MoreSearching for patients to test the effectiveness of venetoclax with ibrutinib in treating chronic lymphocytic leukemis
In a nutshell This phase 2 clinical trial will test the effectiveness of ibrutinib (Imbruvica) with venetoclax (Venclexta) in treating patients with chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the response to treatment. This trial is being conducted at the University of Texas MD Anderson Cancer Center in Houston,...
Read MoreIs stem cell transplantation a viable option among AML patients who are not in remission?
In a nutshell This study examined stem cell transplant outcomes across acute myeloid leukemia (AML) patients with different disease status. Researchers reported superior survival after a stem cell transplant among patients in second complete remission. Some background Stem cell transplantation is considered the most effective therapy for...
Read More
